PDE5A and pulmonary arterial hypertension: Patients on monotherapy (of the patients on monotherapy, 64.7% were incident and 35.3% were prevalent) started macitentan after a median (Q1-Q3) of 3.3 (0.4–13.7) months after PAH diagnosis while patients on combination with a PDE5 inhibitor (of the patients on this combination, 30.6% were incident and 69.4% were prevalent) initiated macitentan after a median (Q1-Q3) of 23.0 (2.6–59.0) months.